FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018947211> ?p ?o ?g. }

• W2018947211 endingPage "334" @default.
• W2018947211 startingPage "327" @default.
• W2018947211 abstract "Summary. Antiangiogenesis agents are now being used in clinical trials to reduce the risk of recurrence of cancer. Several of these agents, however, are associated with thrombosis, especially when used in combination with chemotherapy. Antiangiogenesis and thrombosis are both endothelial-related activities, and we therefore evaluated one presumed antiangiogenesis agent (thalidomide) on intact cultured endothelial cells, and on cultured endothelial cells injured by preincubation with doxorubicin. We evaluated cell viability, caspase-3 activation, morphology of cells using light microscopy, and protease activated receptor-1 (PAR-l) expression. In our experiments, doxorubicin induced a dose- and incubation time-dependent and caspase-3-mediated apoptosis of endothelial cells. Thalidomide alone caused no changes in intact endothelial cells in terms of morphology, cell viability or activation of caspase-3. In contrast, when thalidomide was added to doxorubicin-injured endothelial cells, there was protection from cell death, increase in viability of endothelial cells, induction of differentiation and formation of neotubules. Doxorubicin reduced the expression of thrombin receptor, PAR-1, as evaluated by immunostaining and flow cytometry. Thalidomide did not alter PAR-1 expression in untreated cells but restored its expression reduced by doxorubicin. These findings suggest that thalidomide may be procoagulant, not by enhancing doxorubicin-mediated endothelial cell injury, but by altering the expression of PAR-1 on injured endothelium and resulting in endothelial dysfunction, which may explain hypercoagulability in patients treated with chemotherapy followed by thalidomide." @default.
• W2018947211 created "2016-06-24" @default.
• W2018947211 creator A5004237150 @default.
• W2018947211 creator A5013765402 @default.
• W2018947211 creator A5025789544 @default.
• W2018947211 creator A5027296636 @default.
• W2018947211 date "2004-02-01" @default.
• W2018947211 modified "2023-10-18" @default.
• W2018947211 title "Thalidomide protects endothelial cells from doxorubicin‐induced apoptosis but alters cell morphology" @default.
• W2018947211 cites W1656256413 @default.
• W2018947211 cites W1658693572 @default.
• W2018947211 cites W1990191742 @default.
• W2018947211 cites W1994805429 @default.
• W2018947211 cites W1999565376 @default.
• W2018947211 cites W2002354251 @default.
• W2018947211 cites W2006563516 @default.
• W2018947211 cites W2007687693 @default.
• W2018947211 cites W2021024250 @default.
• W2018947211 cites W2033711861 @default.
• W2018947211 cites W2037103210 @default.
• W2018947211 cites W2046778136 @default.
• W2018947211 cites W2049396239 @default.
• W2018947211 cites W2052119252 @default.
• W2018947211 cites W2060697601 @default.
• W2018947211 cites W2062228528 @default.
• W2018947211 cites W2062302016 @default.
• W2018947211 cites W2081839886 @default.
• W2018947211 cites W2091112630 @default.
• W2018947211 cites W2092557822 @default.
• W2018947211 cites W2093544430 @default.
• W2018947211 cites W2122071242 @default.
• W2018947211 cites W2127206962 @default.
• W2018947211 cites W2129592835 @default.
• W2018947211 cites W2133986577 @default.
• W2018947211 cites W2141836567 @default.
• W2018947211 cites W2142149038 @default.
• W2018947211 cites W2154554320 @default.
• W2018947211 cites W2160621818 @default.
• W2018947211 cites W2167236214 @default.
• W2018947211 cites W2191693046 @default.
• W2018947211 cites W2316160054 @default.
• W2018947211 cites W4232427147 @default.
• W2018947211 doi "https://doi.org/10.1046/j.1538-7933.2003.00573.x" @default.
• W2018947211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14995997" @default.
• W2018947211 hasPublicationYear "2004" @default.
• W2018947211 type Work @default.
• W2018947211 sameAs 2018947211 @default.
• W2018947211 citedByCount "53" @default.
• W2018947211 countsByYear W20189472112012 @default.
• W2018947211 countsByYear W20189472112013 @default.
• W2018947211 countsByYear W20189472112014 @default.
• W2018947211 countsByYear W20189472112015 @default.
• W2018947211 countsByYear W20189472112017 @default.
• W2018947211 countsByYear W20189472112019 @default.
• W2018947211 countsByYear W20189472112020 @default.
• W2018947211 countsByYear W20189472112021 @default.
• W2018947211 countsByYear W20189472112022 @default.
• W2018947211 countsByYear W20189472112023 @default.
• W2018947211 crossrefType "journal-article" @default.
• W2018947211 hasAuthorship W2018947211A5004237150 @default.
• W2018947211 hasAuthorship W2018947211A5013765402 @default.
• W2018947211 hasAuthorship W2018947211A5025789544 @default.
• W2018947211 hasAuthorship W2018947211A5027296636 @default.
• W2018947211 hasConcept C123012128 @default.
• W2018947211 hasConcept C126322002 @default.
• W2018947211 hasConcept C190283241 @default.
• W2018947211 hasConcept C202751555 @default.
• W2018947211 hasConcept C203014093 @default.
• W2018947211 hasConcept C2776364478 @default.
• W2018947211 hasConcept C2776694085 @default.
• W2018947211 hasConcept C2776992346 @default.
• W2018947211 hasConcept C2779609412 @default.
• W2018947211 hasConcept C2781303535 @default.
• W2018947211 hasConcept C502942594 @default.
• W2018947211 hasConcept C53227056 @default.
• W2018947211 hasConcept C55493867 @default.
• W2018947211 hasConcept C71924100 @default.
• W2018947211 hasConcept C86803240 @default.
• W2018947211 hasConcept C98274493 @default.
• W2018947211 hasConceptScore W2018947211C123012128 @default.
• W2018947211 hasConceptScore W2018947211C126322002 @default.
• W2018947211 hasConceptScore W2018947211C190283241 @default.
• W2018947211 hasConceptScore W2018947211C202751555 @default.
• W2018947211 hasConceptScore W2018947211C203014093 @default.
• W2018947211 hasConceptScore W2018947211C2776364478 @default.
• W2018947211 hasConceptScore W2018947211C2776694085 @default.
• W2018947211 hasConceptScore W2018947211C2776992346 @default.
• W2018947211 hasConceptScore W2018947211C2779609412 @default.
• W2018947211 hasConceptScore W2018947211C2781303535 @default.
• W2018947211 hasConceptScore W2018947211C502942594 @default.
• W2018947211 hasConceptScore W2018947211C53227056 @default.
• W2018947211 hasConceptScore W2018947211C55493867 @default.
• W2018947211 hasConceptScore W2018947211C71924100 @default.
• W2018947211 hasConceptScore W2018947211C86803240 @default.
• W2018947211 hasConceptScore W2018947211C98274493 @default.
• W2018947211 hasIssue "2" @default.
• W2018947211 hasLocation W20189472111 @default.
• W2018947211 hasLocation W20189472112 @default.

• next